Endeavor Health

Glenview, Illinois 60201

9 studies enrolling now · 19 studies all time

What they study most

Acute Myocardial Infarction, Acute Pulmonary Embolism, Allergic Reactions, Aortic Valve Stenosis, Autoimmune Small Fiber Neuropathy, Cardiovascular Diseases, Chronic Inducible Urticaria, Chronic Spontaneous Urticaria, Chronic Urticaria (CU): Chronic Inducible Urticaria (CINDU) and Chronic Spontaneous Urticaria (CSU), Coronary Arterial Disease (CAD), Coronary Artery Calcification, Coronary Artery Disease

Studies at this site

• Parasternal Extravascular ICD System Pivotal Clinical Investigation (ALARION EV) Study — Recruiting now
• AGENT DCB STANCE: Safety and Effectiveness Study of AGENT Drug-Coated Balloon Compared to Standard of Care Percutaneous Coronary Intervention (PCI) Treatment for de Novo Coronary Lesions — Recruiting now
• Study of Remibrutinib (LOU064) Efficacy and Safety and Exploration of Its Mechanism of Action in Participants With Chronic Urticaria — Recruiting now
• Patient Quality of Recovery After TAVR With Different Sedation Regimens — Recruiting now
• Study Evaluating the Safety and Efficacy of Neffy or Intramuscular Adrenalin in Patients With Allergic Reactions After Oral Food Challenge or Allergen Immunotherapy — Recruiting now
• IVIG in the Treatment of Autoimmune Small Fiber Neuropathy With TS-HDS, FGFR-3, or Plexin D1 Antibodies — Recruiting now
• WATER IV PCa (AS Sub-study) — Starting soon
• A Prospective, Randomized Multicenter Clinical Trial of the TricValve® Transcatheter Bicaval Valve System in Subjects With Severe Tricuspid Regurgitation. — Starting soon
• TECTONIC CAD IVL IDE Study — Running, not enrolling
• Selatogrel Outcome Study in Suspected Acute Myocardial Infarction — Enrolling by invitation
• 24 Weeks Double-blind Randomized Placebo-controlled Trial to Evaluate Efficacy, PK, Safety of LOU064 in Adolescents (12 - <18) With CSU and Inadequate Response to H1-antihistamine Followed by Optional 3 Years Open-label Extension and an Optional 3 Years Safety Long-term Treatment-free Follow-up — Running, not enrolling
• A Study to Investigate Efficacy, Safety, and Tolerability of Remibrutinib Compared With Placebo in Adults With CINDU Inadequately Controlled by H1-antihistamines — Running, not enrolling
• A Phase 3 Study to Assess Efficacy Safety and Tolerability of Remibrutinib in Adult and Adolescent Patients With Moderate to Severe Hidradenitis Suppurativa — Running, not enrolling
• WATER IV Prostate Cancer — Running, not enrolling
• Extension Study to Assess Effects of Non-interrupted Versus Interrupted and Long Term Treatment of Two Dose Regimes of Secukinumab in Subjects With Hidradenitis Suppurativa — Running, not enrolling
• An Extension Study of Long-term Efficacy, Safety and Tolerability of Remibrutinib in Chronic Spontaneous Urticaria Patients Who Completed Preceding Studies With Remibrutinib — Running, not enrolling
• A Multicenter, Open-label Phase 3 Study: Ambulatory Blood Pressure Monitoring in Adult Patients With Chronic Spontaneous Urticaria Inadequately Controlled by H1-antihistamines Treated With Remibrutinib up to 12 Weeks. — Completed
• SYMPHONY-PE Study for Treatment of Pulmonary Embolism — Completed
• Paired-Ring Mitral Annuloplasty Ring Sizing Device — Running, not enrolling